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Introduction: Accurate assessment of HER2 status is critical in determining appropriate therapy for breast cancer
patients but the best HER2 testing methodology has yet to be defined. In this study, we compared quantitative HER2
expression by the HERmark™ Breast Cancer Assay (HERmark) with routine HER2 testing by immunohistochemistry (IHC)
and fluorescence in situ hybridization (FISH), and correlated HER2 results with overall survival (OS) of breast cancer
patients in a multicenter Collaborative Biomarker Study (CBS).
Methods: Two hundred and thirty-two formalin-fixed, paraffin-embedded breast cancer tissues and local laboratory
HER2 testing results were provided by 11 CBS sites. HERmark assay and central laboratory HER2 IHC retesting were
retrospectively performed in a blinded fashion. HER2 results by all testing methods were obtained in 192 cases.
Results: HERmark yielded a continuum of total HER2 expression (H2T) ranging from 0.3 to 403 RF/mm2 (approximately
3 logs). The distribution of H2T levels correlated significantly (P <0.0001) with all routine HER2 testing results. The
concordance of positive and negative values (equivocal cases excluded) between HERmark and routine HER2 testing
was 84% for local IHC, 96% for central IHC, 85% for local FISH, and 84% for local HER2 status. OS analysis revealed
a significant correlation of shorter OS with HER2 positivity by local IHC (HR = 2.6, P = 0.016), central IHC (HR = 3.2,
P = 0.015), and HERmark (HR = 5.1, P <0.0001) in this cohort of patients most of whom received no HER2-targeted
therapy. The OS curve of discordant low (HER2 positive but H2T low, 10% of all cases) was aligned with concordant
negative (HER2 negative and H2T low, HR = 1.9, P = 0.444), but showed a significantly longer OS than concordant
positive (HER2 positive and H2T high, HR = 0.31, P = 0.024). Conversely, the OS curve of discordant high (HER2 negative
but H2T high, 9% of all cases) was aligned with concordant positive (HR = 0.41, P = 0.105), but showed a significantly
shorter OS than concordant negative (HR = 41, P <0.0001).
Conclusions: Quantitative HER2 measurement by HERmark is highly sensitive, accurately quantifies HER2 protein
expression and correlates well with routine HER2 testing. When HERmark and local HER2 results were discordant,
HERmark more accurately predicted overall survival.* Correspondence: dyardley@tnonc.com
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Overexpression of human epidermal growth factor re-
ceptor 2 (HER2) occurs in approximately 15 to 20% of
primary breast carcinomas and is associated with poor
prognosis [1,2]. HER2 tumor positivity is also a signifi-
cant predictive factor for response to HER2-targeted
therapies such as trastuzumab (Herceptin™), pertuzumab
(Perjeta™), lapatinib (Tykerb™) or trastuzumab emtansine
(T-DM1, Kadcyla™) [3-6]. Determination of the HER2
status for all invasive breast cancers at primary diagnosis
is now the standard of care [7,8] and can be assessed by
various HER2 testing methodologies. While slide-based
HER2 assessments on formalin-fixed, paraffin-embedded
(FFPE) breast cancer tissues are utilized, routine HER2
testing is subject to significant interlaboratory variation
that may result in discrepant results in approximately
20% of routine HER2 testing in the community [7-10].
Reasons for discordance between laboratory HER2
results are complex and include differences in laboratory
proficiencies and performances as well as interpretation
of HER2 testing results. This has formed the basis of the
expert American Society of Clinical Oncology (ASCO)
and the College of American Pathologists (CAP) panel
in 2007 to develop guidelines to improve the accuracy of
HER2 testing in breast cancer [7]. Recently published
reports continue to show lack of concordance for HER2
results between laboratories despite significant emphasis
and progress made to standardize routine HER2 testing
post publication of the ASCO/CAP guidelines for HER2
testing in 2007 [11-13]. Since then, clarifications and
updates to the ASCO/CAP HER2 testing guidelines have
been issued, and ASCO and CAP convened to conduct a
formal and comprehensive review and revised the guide-
lines in 2013 [8]. The main objective of HER2 testing
remains to accurately determine which patients may
benefit from HER2-based targeted therapies.
The HERmark™ Breast Cancer Assay (HERmark,
Monogram Biosciences, South San Francisco, CA, USA)
is a validated novel HER2 testing method that provides
accurate quantification of HER2 protein in FFPE tissue
samples [14,15]. The HERmark assay uses a dual-
antibody, proximity-based immunoassay approach, the
VeraTag™ technology (Monogram Biosciences), to make
precise and quantitative measurement of total HER2
protein expression (H2T) with greater sensitivity and
specificity than immunohistochemistry (IHC), and pro-
vides a continuum of H2T values over approximately a
1,000-fold dynamic range in human breast cancers and
cell lines [15]. The utilization of capillary electrophoresis
for HER2 signal quantification in the HERmark assay
yields results that are independent of an observer’s sub-
jective interpretation of HER2 signal intensity. A clinical
study showed that when breast cancer HER2 expression
was measured using the HERmark assay, breast cancerpatients with advanced disease whose tumors were
HER2 positive by fluorescence in situ hybridization
(FISH) but H2T low by HERmark had similar outcomes
(as measured by time to progression, following treat-
ment with trastuzumab) as those patients whose cancers
were FISH negative and H2T low, thus identifying HER2
FISH-positive tumors with a poorer response to trastu-
zumab, relative to those tumors which were both HER2
positive by FISH and H2T high by HERmark [16]. These
data suggest that HERmark may serve as a novel alterna-
tive for quantitative HER2 assessment and provide added
value to routine HER2 testing. The aims of the current
study were to evaluate the concordance of HER2 results
between HERmark and routine HER2 testing methods,
and to correlate the results obtained by various HER2
methods with overall survival (OS) of breast cancer
patients in a multicenter Collaborative Biomarker Study
(CBS) involving 11 study sites.
Methods
Patient population
This retrospective, multicenter Collaborative Biomarker
Study included women who had tumor tissues from rou-
tine surgical excision of invasive breast cancer between
January 2000 and May 2005 from the following study
sites: Sarah Cannon Research Institute (Nashville, TN,
USA)/Tennessee Oncology, PLLC, (Nashville, TN, USA),
Dartmouth Hitchcock Medical Center (Lebanon, NH,
USA), Texas Oncology Bedford (Bedford, TX, USA),
Texas Oncology and Medical City (Dallas, TX, USA), St.
Jude Heritage Medical Group (Fullerton, CA, USA), the
Center for Cancer and Hematologic Disease (Cherry
Hill, NJ, USA), Monroe Medical Associates (Harvey, IL,
USA), Swedish American Regional Medical Center
(Rockford, IL, USA), the West Clinic (Memphis, TN,
USA), Arlington Cancer Center (Arlington, TX, USA), and
Wilshire Oncology Medical Group (Rancho Cucamonga,
CA, USA). Institutional review board (IRB) approval for
the study was conducted by the Western Institutional
Review Board (WIRB, Olympia, WA, USA) for our spon-
sor approval and site IRB approvals. The study was
granted a waiver for informed consents and a waiver for
authorization under HIPAA, which we specifically re-
quested due to the nature of the study and likelihood that
many of the patients whose tumors we studied were now
deceased or lost to follow-up. The WIRB determined that
this study qualifies for a waiver of consent under 45 CFR
46.116(d). The Board also approved our request for a
waiver of authorization for use and disclosure of protected
health information (PHI) for the study. Tissue samples
and clinical data were anonymized. A total of 232 FFPE
breast cancer blocks were collected by the 11 CBS study
sites with a median of 22 (range 5 to 27) cases per site.
The study was designed to enroll approximately 50% cases
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status as determined by study sites based on local HER2
testing. Freshly cut 5-micron unstained tissue sections
were prepared on positively charged glass slides by study
sites and sent to Monogram Biosciences for HERmark
assay and central HER2 IHC retest in a blinded fashion.
Patient-deidentified pathology reports were reviewed and
clinicopathological data, including demographics, tumor
characteristics, hormone receptor status, treatment (in-
cluding HER2-targeted therapy received), prior HER2 test-
ing results, and OS data, were collected by study sites, and
sent to Monogram Biosciences following the site’s receipt
of each patient’s HERmark result.
The HERmark™ Breast Cancer Assay
Total HER2 protein expression (H2T) was quantified
using the HERmark assay as previously described
[14,15,17]. Briefly, H2T was detected through the
proximity-based release of a fluorescent tag conjugated
via a cleavable thioether tether, to a monoclonal anti-
body directed against the cytoplasmic domain of HER2
(Ab8, LabVision, part of Thermo Fisher Scientific,
Waltham, MA, USA). The antibody was paired with a
biotinylated second antibody directed against the C-
terminus of HER2 (Ab15, LabVision, part of Thermo
Fisher Scientific). Upon illumination with red light, the
photosensitizer molecule linked to the second biotinyl-
ated Ab15 liberates singlet oxygen that cleaves any
neighboring thioether bonds, thus releasing VeraTag™
reporters in close proximity. Reporter signal quantified
by capillary electrophoresis was normalized to invasive
tumor area on the FFPE tissue section. The final value
for H2T expression (relative fluorescence (RF)/mm2
tumor) was calculated as (RF concentration) × (illu-
mination buffer volume)/(tumor area). A total of 194
(84%, 194/232) collected cases were determined to
have adequate invasive breast cancer tissues and
yielded valid H2T results by HERmark assay. The
HERmark assay was performed and H2T results were
determined, blinded to local HER2 results and case
report form data including clinical outcomes and treat-
ment information. The continuous H2T results were
categorized as HERmark negative, HERmark equivocal,
and HERmark positive with predefined H2T analytical
cutoff values (<10.5, 10.5 to 17.8, and >17.8 RF/mm2,
respectively [17]). A pre-defined, published HERmark
clinical cutoff (13.8 RF/mm2 [16]) was also used to
define H2T levels as H2T low and H2T high in OS
analysis.
Central HER2 immunohistochemistry (IHC) retesting
Central laboratory HER2 IHC retest was performed at
the Center for Molecular Biology and Pathology (CMBP,
Laboratory Corporation of America, Inc., Research TrianglePark, NC, USA), using the HercepTest™ (DAKO, Glostrup,
Denmark). A total of 192 (99%) of the 194 cases that
had H2T results yielded valid HER2 IHC results.
Central HER2 IHC retest was performed and analyzed
blinded to HERmark and local HER2 results. The IHC
staining intensity was scored as 0, 1+, 2+, or 3+ and
categorized as HER2 IHC negative, equivocal, or posi-
tive according to the ASCO/CAP guideline recommen-
dations for HER2 testing [7].
Local HER2 testing results
Each study site collected and reported HER2 IHC
(defined as local IHC in this study) and/or HER2 FISH
(defined as local FISH) results for each case. In addition,
each study site reported a final clinical HER2 status
(negative, equivocal, or positive, and defined as local
HER2 status or investigator-determined HER2 status)
based on the combination of all available local HER2 re-
sults for each case. Local IHC was reported as 0, 1+, 2+,
or 3+ staining as well as IHC negative, equivocal, or
positive as determined by study sites. Local FISH was re-
ported as HER2 amplified or HER2 non-amplified only,
and information on HER2/CEP17 ratio was not available
for this study. No FISH equivocal case was submitted.
Local FISH results were available in 67 (35%) of the 194
cases that had H2T results.
Statistical analysis
The agreement between HERmark and HER2 IHC,
HER2 FISH- or investigator-determined HER2 status
was analyzed according to the number of tumors defined
for each category divided by the total number of study
patients. Differences in continuous H2T values among
various categorical HER2 subgroups defined by routine
HER2 testing methods were analyzed using the Mann-
Whitney test or the Jonckheere-Terpstra test. Overall
concordance that included all HER2 categories as well as
positive/negative concordance that excluded equivocal
HER2 cases was analyzed in accordance with the ASCO/
CAP HER2 testing guidelines [7]. Kappa statistics were
used to evaluate concordance between HERmark and
routine HER2 testing methods. OS was defined as the
time from initial diagnosis of invasive breast cancer to
death or censor. Estimates of survival were based on the
Kaplan-Meier (KM) method and statistical significance
of differences was evaluated by the log-rank test.
Results
Patient and tumor characteristics
Patient clinicopathological characteristics are summa-
rized in Table 1. A total of 194 samples that had quanti-
tative HER2 measurements by HERmark were included
for analysis. Median age was 51 years (range 27 to 84
years). The majority of tumor samples were of primary
Table 1 Clinicopathological characteristics of the study
population
Parameter No. % (range)
Sample size 194
Median length of follow-up (months) 193 67.1 (14.8 - 302.8)









Not reported 15 8%
Tissue source
Primary breast 187 96%
Other* 7 4%
Tumor histology
Invasive ductal carcinoma 172 89%
Invasive lobular carcinoma 14 7%
Other histologic type** 8 4%
Median tumor size (cm) 185 2.1 (0.4 - 14)
Not reported 9
Tumor grade
Grade 1 (well) 17 9%
Grade 2 (moderate) 49 25%
Grade 3 (poor) 93 48%
Not reported 35 18%





Not reported 4 2%
Nodal status at initial diagnosis
Node positive 89 46%
Node negative 66 34%








Table 1 Clinicopathological characteristics of the study
population (Continued)
IHC 2+/FISH positive 2 7%
IHC 2+/FISH negative 18 60%






Hormone receptor (ER/PR) status
Positive 141 73%
Negative 53 27%
ER and PR status
ER (+), PR (+) 110 57%
ER (+), PR (−) 30 15%
ER (−), PR (+) 1 1%




*Other tissue sources: skin, supraclavicular, sentinental lymph node, axillary lymph
node, ovary, lung, chest wall; **other histologic type: ‘invasive mammary’ (5), breast
adenocarcinoma (1), infiltrating mucinous, adenocarcinoma (1), and metastatic
carcinoma (1); #trastuzumab- and/or lapatinib-containing therapy. ER, estrogen
receptor; FISH, fluorescence in situ hybridization; HER2, human epidermal growth
factor receptor 2; IHC, immunohistochemistry; PR, progesterone receptor.
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(89%), moderately to poorly differentiated (73%), stage I
or II at initial diagnosis (71%), and hormone receptor
status (estrogen receptor (ER)/progesterone receptor
(PR)) positive (73%). Local HER2 status was reported by
the study sites as 57% HER2 negative, 43% HER2 posi-
tive and 1% HER2 equivocal. Only 10% of patients were
reported to have received targeted HER2 therapy (trastu-
zumab and/or lapatinib, Table 1). This retrospective
study included women who had tumor tissues from rou-
tine surgical excision of invasive breast cancer between
January 2000 and May 2005. HER2-targeted therapy was
not FDA approved outside of clinical trials for neoadju-
vant or early-stage breast cancer therapy during the
study period. The median follow-up time was 67.1
months (range 14.8 to 302.8 months).
Comparison of HER2 results and various testing methods
The distribution of quantitative total HER2 expression
(H2T) was compared with categorical results of routine
HER2 tests (Figure 1). Quantitative H2T values ranged
from 0.3 to 403 RF/mm2 on a continuum for the entire
cohort. In comparison with local IHC, the H2T levels
ranged from 0.5 to 30.1 (median 4.4) for IHC 0, from 1.0
H2T by HERmark
0.2














Local FISH (-) 
Local FISH (+)
Local HER2 status (-)
Local HER2 status Eqv.
Local HER2 status (+)
HERmark negative HERmark positive Eqv.
Figure 1 Distribution of quantitative total HER2 expression (H2T) in routine HER2 tests. HERmark equivocal (Eqv.) zone is defined within
the two green vertical lines. Short vertical red line indicates the median of a H2T distribution. FISH, fluorescence in situ hybridization; HER2, human
epidermal growth factor receptor 2; H2T, quantitative total HER2 expression by HERmark; IHC, immunohistochemistry.
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12.5) for IHC 2+, and from 3.3 to 403 (median 59.6) for
IHC 3+. Higher H2T levels were significantly associated
with stronger IHC staining intensity in the four sub-
groups by local IHC testing (P <0.0001, Jonckheere-
Terpstra test). For central IHC retest cases, the H2T
levels ranged from 0.3 to 14.3 (median 3.8) for IHC 0,
from 2.6 to 30.1 (median 8.1) for IHC 1+, from 3.1 to
163 (median 11.7) for IHC 2+, and from 6.4 to 403 (me-
dian 86.5) for IHC 3+. Higher H2T levels were signifi-
cantly associated with stronger IHC staining intensity in
the four central IHC subgroups (P <0.0001, Jonckheere-
Terpstra test). In comparison with local FISH, the H2T
levels ranged from 1.5 to 48.4 (median 7.6) for FISH
negative and from 0.3 to 403 (median 65.7) for FISH
positive. In comparing H2T levels in FISH-negative
versus FISH-positive groups, we observed significantly
higher H2T in the FISH-positive group (P <0.0001,
Mann-Whitney test). For local HER2 status, the H2T
levels ranged from 0.5 to 65.0 (median 5.7) for HER2
negative and from 0.3 to 403 (median 57.4) for HER2
positive. Higher H2T levels were significantly associ-
ated with local HER2 status positive (P <0.0001,
Mann-Whitney test). The sole case of local HER2status equivocal had an H2T value of 5.8 and therefore
was categorized as HERmark negative.
The comparison between HERmark and routine HER2
tests is presented in Table 2. The overall concordance of
all three categories (negative, equivocal, and positive)
between HERmark and routine HER2 testing was 68%
(kappa 0.475) for local IHC, 69% (kappa 0.481) for cen-
tral IHC, and 73% (kappa 0.510) for local HER2 status.
Analysis of overall concordance between HERmark and
local FISH was not performed because there was no
FISH equivocal case reported by study sites. When
equivocal cases were excluded from all HER2 results, the
concordance of positive and negative values between
HERmark and routine HER2 testing was 84% (kappa
0.676) for local IHC, 96% (kappa 0.914) for central IHC,
85% (kappa 0.705) for local FISH, and 84% (kappa 0.682)
for local HER2 status.
Kaplan-Meier overall survival analyses by HER2 status as
stratified by different HER2 testing methods
The Kaplan-Meier overall survival (OS) analysis was per-
formed on cases that had HER2 testing results and avail-
able survival data in 177 cases with local IHC, 188 cases
with central IHC, 65 cases with local FISH, 190 cases
Table 2 Concordance of HERmark with local HER2 IHC, central HER2 IHC, local HER2 FISH, and local clinical HER2 status
Local HER2 IHC Central HER2 IHC Local HER2 FISH Local clinical HER2 status
Negative Equivocal Positive Total IHC Negative Equivocal Positive Total IHC Non-
amplified
Amplified Total FISH Negative Equivocal Positive Total HER2
N % N % N % N % N % N % N % N % N % N % N % N % N % N % N %
HERmark Negative 69 71% 14 14% 14 14% 97 51% 86 86% 13 13% 1 1% 100 52% 27 90% 3 10% 30 45% 83 83% 1 1% 16 16% 100 52%
HERmark Equivocal 10 38% 9 35% 7 27% 26 14% 17 71% 5 21% 2 8% 24 13% 11 92% 1 8% 12 18% 17 65% 0 0% 9 35% 26 13%
HERmark Positive 9 13% 7 10% 52 76% 68 36% 4 6% 23 34% 41 60% 68 35% 5 20% 20 80% 25 37% 10 15% 0 0% 58 85% 68 35%
Total 88 46% 30 16% 73 38% 191 100% 107 56% 41 21% 44 23% 192 100% 43 64% 24 36% 67 100% 110 57% 1 1% 83 43% 194 100%
Overall
concordance
68%, (69 + 9 + 52)/191 69%, (86 + 5 + 41)/192 NA# 73%, (83 + 0 + 58)/194
Kappa (CI 95%),
overall
0.475 (0.373 to 0.578);
weighted Kappa = 0.545
0.481 (0.386 to 0.576);
weighted Kappa = 0.631
0.510 (0.409 to 0.610);
weighted Kappa = 0.583
Concordance,
excluding Eqv.*
84%, (69 + 52)/(69 + 9 + 14 + 52) 96%, (86 + 41)/(86 + 4 + 1 + 41) 85%, (27 + 20)/(27 + 5 + 3 + 20) 84%, (83 + 58)/(83 + 10 + 16 + 58)
Kappa (CI 95%),
excluding Eqv.
0.676 (0.550 to 0.797) 0.914 (0.841 to 0.988) 0.705 (0.516 to 0.893) 0.682 (0.570 to 0.794)
*Equivocal (Eqv.) cases from both tests were excluded; #NA, overall concordance was not calculated for 2 x 3 table. Central HER2 IHC retesting was performed retrospectively and central HER2 status was defined per
ASCO/CAP guidelines for HER2 testing [7]. The results of local HER2 testing were reported by participating study sites based on local IHC and/or local FISH. Percentages may not add up to 100% due to rounding.
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(Figure 2). Local IHC positive (IHC 3+) was associated
with a significantly shorter OS compared with local IHC



















Local IHC positive (n=72)
Local IHC equivocal (n=28)
Local IHC negative (n=77)





















Local FISH positive (n=24)
Local FISH negative (n=41)
A
C
Local FISH positive vs. negative:
Log-rank P =0.90,  HR,1.1 (95% CI, 0.36 to 3.2) 
Local IHC positive vs. negative:
Log-rank P =0.016,  HR, 2.6 (95% CI, 1.2 to 5.6) 
























HERmark positive vs. negative:
Log-rank P < 0.0001,  HR, 5.1 (95% CI, 2.3 to 11) 
Figure 2 Kaplan-Meier overall survival analyses by HER2 status. (A) Lo
status, (E) HERmark HER2 status, and (F) quantitative total HER2 (H2T) level
sites. Central HER2 IHC retest was performed retrospectively and categorize
was categorized as HERmark negative, HERmark equivocal, or HERmark pos
high were defined by a predetermined H2T clinical cutoff [16]. CI, confiden
epidermal growth factor receptor 2; H2T, quantitative total HER2 expression2.6; 95% confidence interval (CI), 1.2 to 5.6; P = 0.016).
OS for local IHC equivocal (IHC 2+) was similar to that
of local IHC positive (Figure 2A: HR = 1.0; 95% CI, 0.43




















Central IHC positive (n=42)
Central IHC equivocal (n=41)
Central IHC negative (n=105)




















Local HER2 status positive (n=82)
Local HER2 status negative (n=108)
B
D
Local HER2 status positive vs. negative:
Log-rank P = 0.098,  HR, 1.8 (95% CI, 0.90 to 3.5) 
Central IHC positive vs. negative:
Log-rank P =0.015,  HR, 3.2 (95% CI, 1.3 to 8.2) 























H2T high vs. H2T low:
Log-rank P < 0.0001,  HR, 5.6 (95% CI, 2.8 to 11) 
cal HER2 IHC, (B) central HER2 IHC, (C) local HER2 FISH, (D) local HER2
s. The results of local HER2 tests were reported by participating study
d per ASCO/CAP guidelines for HER2 testing [7]. HERmark HER2 status
itive by predefined H2T analytical cutoff values [17]. H2T low and H2T
ce interval; FISH, fluorescence in situ hybridization; HER2, human
by HERmark; HR, hazard ratio; IHC, immunohistochemistry.
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0.82 to 9.2; P = 0.10). Similarly, central IHC positive was
associated with a significantly shorter OS compared with
central IHC negative (Figure 2B: HR = 3.2; 95% CI, 1.3 to
8.2; P = 0.015). OS in central IHC equivocal was similar
to that of central IHC positive (Figure 2B: HR = 0.96;
95% CI, 0.41 to 2.3; P = 0.93) and showed a trend (near
statistically significant) of shorter OS compared with
the central IHC negative (HR = 2.5; 95% CI, 1.0 to 6.5;
P = 0.051). Local FISH positive did not show significant
differences in OS compared with local FISH negative
(Figure 2C: HR = 1.1; 95% CI, 0.36 to 3.2; P = 0.90).
Investigator-determined HER2-positive status corre-
lated with a trend of shorter OS compared with HER2-
negative status (Figure 2D: HR = 1.8; 95% CI, 0.90 to
3.5 P = 0.098). HERmark positive was associated with a
significantly shorter OS compared with HERmark nega-
tive (Figure 2E: HR = 5.1; 95% CI, 2.3 to 11; P <0.0001).
OS of HERmark equivocal was similar to that of HER-
mark positive (Figure 2E: HR = 0.62; 95% CI, 0.26 to
1.5; P = 0.29), and showed a trend of shorter OS com-






























































 Patient groups HER2 results N %
A. Discordant high local HER2 (-), H2T high 17 9%
B. Concordant negative local HER2 (-), H2T low 91 48%
C. Concordant positive local HER2 (+), H2T high 63 33%
D. Discordant low local HER2 (+), H2T low 19 10%
Total: 190 100%
Figure 3 Overall survival and HER2 status as stratified by local HER2
(B) Kaplan-Meier overall survival analyses for corresponding HER2-H2T conc
the median of a H2T distribution. HER2, human epidermal growth factor rece
ratio; P, the P value of log-rank test.0.82 to 12; P = 0.093). H2T high (H2T >13.8) was associ-
ated with a significantly shorter OS compared with H2T
low (Figure 2F: HR = 5.6, 95% CI, 2.8 to 11; P <0.0001).
When OS analysis for H2T levels was restricted to pa-
tients who had not received any HER2-targeted therapy,
similar results were observed, showing that H2T high
status was associated with a significantly shorter OS
compared with H2T low status (HR = 4.7, 95% CI, 1.7
to 13; P = 0.003).
The OS correlation between local HER2 status and
H2T levels was further explored by plotting the distribu-
tion of quantitative H2T levels versus the corresponding
local HER2 status and by comparing outcomes in four
groups defined by concordant or discordant results using
the HERmark H2T clinical cutoff (H2T = 13.8, Figure 3).
The distribution of high or low H2T values in local HER2-
negative and HER2-positive groups overlapped and re-
sulted in four subgroups of H2T distribution (Figure 3A):
(1) patients who were HER2 status negative and H2T low
(concordant negative, N = 91, 48%), (2) patients who were
HER2 status positive and H2T high (concordant positive,
N = 63, 33%), (3) patients who were HER2 status positiveTime Since Diagnosis (months)











Survival Comparison HR P 
Concordant positive vs.  Concordant negative 4.7 0.0002
Concordant positive vs.  Discordant high 0.41 0.105
Discordant high vs.  Concordant negative 41 <0.0001
Concordant negative vs.  Discordant low 1.9 0.444
Discordant low vs.  Concordant positive 0.31 0.024
Discordant high vs.  Discordant low 8.3 0.004
status and H2T levels. (A) H2T distribution by local HER2 status.
ordant and discordant groups. Short horizontal red line in (A) indicates
ptor 2; H2T, quantitative total HER2 expression by HERmark; HR, hazard
Yardley et al. Breast Cancer Research  (2015) 17:41 Page 9 of 13but H2T low (discordant low, N = 19, 10%) and (4)
patients who were HER2 status negative but H2T high
(discordant high, N = 17, 9%).
Differences in patient clinicopathological characteris-
tics of the concordant and discordant groups are sum-
marized in Table 3. Compared to the concordant
negative, cases of the concordant positive were signifi-
cantly associated with higher tumor grade, higher stage
at initial diagnosis, positive nodal status, and negative
hormone receptor status. However, no statistically signifi-
cant differences in the clinicopathological characteristics
were found between the two groups that were discordant
between local HER2 status and H2T high/low.
Cox proportional hazards multivariate analyses were
then conducted to evaluate correlation of HERmark
subgroups with OS in the context of clinicopathologi-
cal variables that showed significant differences be-
tween concordant negative and concordant positive
(Table 4). Two different sets of cut points were used to
define HERmark subgroups for the analyses. In Model
A, the ‘analytical cut points’, that is <10.5, 10.5 to 17.8
and >17.8 RF/mm2, were established from HERmark
validation study in which H2T values were compared
with central HER2 IHC/in situ hybridization (ISH) results
[17]. The analytical cut points, which define HERmark
negative, HERmark equivocal, and HERmark positive, are
often used to determine HERmark HER2 status and to
compare routine HER2 status by IHC/ISH with HERmark.
In Model B, the ‘clinical cutoff ’, that is 13.8 RF/mm2, wasTable 3 Clinicopathologic characteristics of HER2 status-HERm
Concordant negative Conc
HER2 -, H2T low HER2
Parameter No. % No.
Tumor size (cm)
<2 45 51% 30
>2 43 49% 31
Tumor grade
Grade 1 and Grade 2 41 54% 10
Grade 3 35 46% 43
Stage at initial diagnosis
I and II 73 83% 40
III and IV 15 17% 22
Nodal status at diagnosis
Node negative 40 55% 15
Node positive 33 45% 38
Hormone receptor (ER/PR) status
Negative 19 21% 23
Positive 72 79% 40
*P <0.05. Fisher exact test was performed for each parameter between two concord
HER2, human epidermal growth factor receptor 2; H2T, quantitative total HER2 exprestablished from a HERmark clinical study in which an
optimal H2T cut point was established for the purpose for
identifying better responders in a clinical cohort of breast
cancer patients treated with anti-HER2 therapy [16]. The
clinical cut point, which defines H2T high and H2T low,
is often used to correlate HERmark results with patient
outcome in clinical studies. In both Model A and Model
B, HER2 subgroups by HERmark were identified as inde-
pendent variables that correlate with OS. Patients in
HERmark-positive or H2T-high group exhibited signifi-
cant shorter overall survival compared with patients in
HERmark-negative or H2T-low group, respectively. None
of the other clinicopathological variables (grade, stage,
nodal status, and hormonal status) was identified as an
independent variable that significantly correlated with OS.
Next, we performed Kaplan-Meier analysis to evaluate
OS for the patients in discordant high group or the
discordant low group in comparison with patients in
either the concordant-positive group or the concordant-
negative group (Figure 3B). The concordant-positive
group was associated with a significantly shorter OS
compared with the concordant-negative group (HR =
4.7, 95% CI, 2.1 to 11; P = 0.0002). The discordant-high
group generated an OS curve that tracked with the
concordant-positive group (HR = 0.41, 95% CI, 0.14 to
1.2; P = 0.105), but showed a significantly shorter OS
compared with the concordant-negative group (HR = 41,
95% CI, 8.1 to 212; P <0.0001). The discordant-low
group yielded an OS curve that tracked with theark concordant and discordant groups
ordant positive Discordant low Discordant high
+, H2T high HER2 +, H2T low HER2 -, H2T high
% No. % No. %
49% 9 47% 6 43%
51% 10 53% 8 57%
19%* 6 40% 8 62%
81% 9 60% 5 38%
65% 14 74% 8 47%
35%* 5 26% 9 53%
28% 7 47% 3 25%
72% 8 53% 9 75%
37%* 6 32% 4 24%
63%* 13 68% 13 76%
ant groups, or, between two discordant groups. ER, estrogen receptor;
ession by HERmark; PR, progesterone receptor.
Table 4 Multivariate Cox proportional hazards ratios for
association between HER2 measurements by HERmark,




HERmark positive vs. negative* 3.1 0.034
Grade 3 vs. 1 or 2 2.0 0.26
Stage III or IV vs. I or II 0.93 0.89
Node positive vs. negative 1.7 0.38
Hormone receptor positive vs. negative 0.43 0.071
Model B
H2T high vs. low# 3.9 0.0061
Grade 3 vs. 1 or 2 1.7 0.30
Stage III or IV vs. I or II 0.91 0.84
Node positive vs. negative 1.9 0.26
Hormone receptor positive vs. negative 0.54 0.15
*HERmark status based on HERmark analytical cutoffs in Model A: HERmark
positive - H2T >17.8 relative fluorescence (RF)/mm2; HERmark negative - H2T <10.5
RF/mm2. #HER2 levels based on HERmark clinical cutoff in Model B: H2T
high - H2T >13.8 RF/mm2; H2T low- H2T ≤13.8 RF/mm2. HER2, human epidermal
growth factor receptor 2; H2T, quantitative total HER2 expression by HERmark;
HR, hazard ratio.
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9.9; P = 0.444), but showed a significantly longer OS
compared with the concordant-positive group (HR =
0.31, 95% CI, 0.11 to 0.86; log-rank P = 0.024). In com-
paring the two discordant groups, the discordant-high
group was associated with a significantly shorter OS
compared with the discordant-low group (HR = 8.3, 95%
CI, 1.9 to 35; P = 0.0042). These results indicate that in
the cases with discordance in local HER2 status versus
H2T results, the expected overall survival correlates with
HERmark results rather than with local HER2 status.
Discussion
Despite efforts made in the past decade to improve the
accuracy and standardization of HER2 testing, discord-
ance in HER2 results between laboratories and testing
methodologies persists. The neoadjuvant GeparQuattro
trial reported a rather high rate of discordance of 27%
between central and local evaluation of HER2 status
[12], which is similar to previous reports of inaccurate
local HER2 results in the NSABP B-31 [18] and the
NCCTG N9831 studies [10,19]. A round-robin study re-
ported a pre-adjudication discordance rate of 8% for
HER2 status (both IHC and FISH) among three expert
pathologists from three central laboratories [13], similar
to the results from an international HER2 proficiency
group study performed among five central laboratories
[20]. The main objectives of the current study were to
compare HER2 results between a novel HER2 test(HERmark) and routine HER2 tests (IHC and FISH),
and to correlate HER2 results by various HER2 testing
methods with overall survival of breast cancer patients
from a multicenter Collaborative Biomarker Study.
The quantitative HERmark assay demonstrated a
broad continuum (approximately 3 logs) of HER2 ex-
pression levels in breast cancer samples in this study.
While distribution of H2T values correlated significantly
with all routine HER2 testing methods, higher concord-
ance was observed between HERmark and central IHC
retest as compared to local HER2 tests. This is consist-
ent with previous reports noting higher discordance
between local HER2 testing and central HER2 testing
relative to discordance among central laboratories
[12,18,19]. Thus, the HERmark assay may supplement
existing routine HER2 testing in the ‘real-world’ setting
as an accurate central HER2 test alternative, particularly
for those cases with uncertainty in routine HER2 results,
for example, HER2 equivocal cases and HER2 results
that show inconsistencies with other clinical and patho-
logical parameters. In addition, the highly sensitive HER-
mark assay (approximately seven to ten times more
sensitive than HER2 IHC [14,15]) may serve as a reliable
tool to quantify HER2 expression levels in HER2 non-
overexpressing breast cancers where routine HER2
testing may not be optimized to measure lower levels of
HER2 protein. Interesting data from the NSABP B31
study suggest that HER2 non-overexpressing breast can-
cer may benefit from targeted HER2 therapy [21]. For
HER2 expression that does not meet the threshold for
HER2-positive disease, enrollment into prospective clin-
ical trials is encouraged, such as NCY01275677 (NSABP
B47) that aims to address the benefit of adjuvant HER2-
targeted therapies in tumors with a lower level of HER2
expression. More accurate and quantitative measure-
ment of lower HER2 expression levels may also be help-
ful for ongoing and planned trials of new anti-HER2
therapies, such as investigational anti-HER2 monoclonal
antibodies such as margetuximab and anti-HER2 vac-
cines targeting HER2 non-overexpressing breast cancer
patients [22-24].
We evaluated HER2 status, stratified by routine HER2
testing and HERmark, as a prognostic factor for OS.
Most patients in this study did not receive targeted
HER2 therapy, and thus, positive HER2 status was
expected to correlate with shorter OS. Accordingly, the
results showed that HER2 positivity by local IHC, central
IHC, or HERmark was significantly associated with a
shorter OS compared with HER2 negativity. However,
local FISH did not show significant difference in OS be-
tween FISH-positive and FISH-negative groups. Possible
explanations may include small sample size and selec-
tion bias because only a portion of the cases had under-
gone HER2 FISH testing. Local HER2-positive status,
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patients with HER2-positive tumors for targeted HER2
therapies, showed a trend, but not statistically signifi-
cant, of shorter OS (HR = 1.8, P = 0.098). In contrast,
H2T levels, as predefined by a published HERmark clinical
cutoff [16], demonstrated a significantly shorter OS in
H2T high compared to H2T low (HR = 5.6, P <0.0001).
To further explore the difference in OS between local
HER2 status and HERmark H2T results, we performed
Kaplan-Meier analysis on four HER2-HERmark sub-
groups: concordant negative (HER2 negative and H2T
low), concordant positive (HER2 positive and H2T high),
discordant low (HER2 positive and H2T low), and dis-
cordant high (HER2 negative and H2T high), (Figure 3).
Each discordant group comprises a significant portion
(9 to 10%) of the entire cohort. As expected, the
concordant-positive group was associated with a signifi-
cantly shorter OS when compared with the concordant-
negative group. Where the results of local HER2 status
were discordant with those of HERmark, as in the two dis-
cordant groups, the OS curves were significantly aligned
with those of HERmark results, but not with the local
HER2 status. The results suggest that within the discord-
ant groups, the HERmark results appear to be a better
predictor of OS in this clinical cohort. We attempted to
explore potential underlying reasons for these differences
and compared clinicopathological characteristics of the
two discordant groups (Table 3). While concordant posi-
tives were significantly associated with higher tumor
grade, more advanced stage at initial diagnosis, more posi-
tive nodal status, and higher rate of hormone receptor
negativity, no significant differences were found in these
clinicopathological characteristics between the two dis-
cordant groups. In Cox proportional hazards multivariate
analyses (Table 4), HER2 expression was identified as the
only independent variable that significantly correlates with
OS. Although the sample sizes of the discordant groups
were relatively small, the difference in OS does not appear
to be due to differences in the clinicopathological factors,
but likely due to the ‘miscall’ made by local HER2 status.
If these findings are confirmed with further studies, the
clinical implications can be significant. Importantly, the
results suggest that 10% of breast cancer patients may be
misclassified in routine HER2 testing as false negative,
leading to denial of HER2-targeted therapies for patients
that could benefit from it. On the other hand, patients
misclassified in routine HER2 testing as false positive
(approximately 10%) could lead to the prescribing and
administration of costly and potentially toxic ineffective
treatment with targeted HER2 therapies. Although the
total number of patients selected for anti-HER2 treat-
ment would not change with this scenario, HERmark
may offer more accurate selection of breast cancer
patients for targeted HER2 therapy in a significantproportion (approximately 20%) of patients. Obviously,
cost and turnaround time implications of additional
HER2 tests using a method like HERmark should be
further evaluated. Recently, a study of cost-effectiveness
for expanded HER2 reflex testing was reported [25].
The analysis showed that retesting patients who are
IHC 0, IHC1+, or FISH-negative is projected to be a
cost-effective clinical strategy. The expanded reflex
testing allows for a second opportunity to measure
HER2 status accurately, correcting both handling errors
and testing inconsistency. Similarly, we believe that se-
lective HER2 retest by HERmark for patients who had
discordant or inconclusive HER2 status by IHC/ISH
would also be a cost-effective clinical strategy, which
warrants further investigation.
The strengths of this study include the multicenter set-
ting which represents ‘real-world’ routine HER2 testing
in the field and thus, is relevant to clinical practice.
Evaluation of various HER2 results, including those of
routine local and central HER2 tests coupled with the
novel HERmark HER2 quantification, offers a comprehen-
sive comparison among various HER2 testing methods.
Despite the heterogeneous therapies in the clinical patient
cohort from various study sites, the majority of patients
did not receive HER2-targeted therapy and thus OS is a
relatively reliable clinical outcome in such a setting. The
study has several limitations. The retrospective nature of
this biomarker study carries inherent heterogeneities that
exist not only in the tumor specimens evaluated but also
in patient selection, HER2 testing methods, and treat-
ments. The study was designed to include approximately
50% HER2-positive and 50% HER2-negative cases for
effective comparison of HER2 results by various testing
methods, and thus does not represent HER2 status in a
general population of breast cancer patients in which the
expected rate of HER2 positivity is approximately 15%.
The number of cases in each of the two discordant groups
is relatively small. Thus, the issues with relatively small
groups in a relatively skewed patient population should be
addressed in future studies. Since most patients in this
study did not receive targeted HER2 therapy, further
studies are also needed to investigate anti-HER2 response
in patients of the discordant groups.
Conclusions
The novel HERmark assay offers highly sensitive and
accurate quantification of HER2 protein expression that
has demonstrated excellent concordance with central
HER2 testing and better correlation as a prognostic
factor in OS as compared with ‘real-world’ local HER2
status in a multicenter clinical cohort of breast cancer
patients. The HERmark assay may reclassify 10% of
false-negative patients by conventional tests as truly
positive and 10% who are currently testing false positive
Yardley et al. Breast Cancer Research  (2015) 17:41 Page 12 of 13by conventional tests as negative. Thus, a resultant
change in therapy for 20% of patients may improve the
outcomes for both HER2-negative and -positive cohorts.
Further clinical studies are warranted to confirm these
findings within well-controlled clinical cohorts and clin-
ical trials.
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